Interview with Jacques Servier, Founder, Servier France
Do you feel the industry has changed more over the past ten years than over the entire 40 years before? It’s an optical illusion. People always have had the feelings…
Address: 22, Rue Garnier 92200 Neuilly sur Seine,France
Tel: +33 (0)1 55 72 60 00
Our entire activity is based on three key principles:
• Our chief principle, naturally, is to satisfy the needs of the physicians who prescribe our products and of the patients who benefit from them.
• Just as importantly, we want our research to contribute to the progress of medicine. Research to us is at least as vital as being an industry.
• Our third principle is all the more crucial as it is too often overlooked: it is that every person working for us should find fulfillment through and in what they do.
Figures
• Leading French independent pharmaceutical company
• Second French pharmaceutical company worldwide
• SERVIER is established in 140 countries
• 85% of SERVIER’s sales are achieved internationally
• Consolidated turnover for the 2007/2008 financial year: €3.7 billion
• More than 25% of SERVIER’s turnover is invested in Research and Development
• Worldwide workforce of over 20 000, including nearly 3 000 in Research and Development
• SERVIER contributes 29% of the trade surplus of France’s pharmaceutical industry
Osteoporosis
Diabetes
Cardiovascular
Venous Diseases
Do you feel the industry has changed more over the past ten years than over the entire 40 years before? It’s an optical illusion. People always have had the feelings…
A physician sending off a quick update to a patient via smartphone; a medical caretaker receiving an alert message that a patient’s medical device requires immediate attention. These are no…
While assessing patient perspectives in comprehensive drug and treatment analyses may sound like a contemporary issue, the Mapi Group has been a pioneer in the practice for over forty years.…
Lyonbiopole was established in 2005 as a cluster designed to support the local business community focused on infectious diseases and microbiology. Philippe Archinard, the Biopole’s president, traces the evolution of…
GEODIS MD Stéphanie Hervé speaks about the company’s consolidated pharmaceutical logistics market with the 2011 acquisition of pre-wholesaler Pharmalog as well as the recent acquisition of OHL in the United…
Mr Kimelfeld and Ms Labat run us through the exceptional history of Lyon and the region in the life sciences field, how Lyon is considered to be the birthplace of…
Pharmaceuticals do not appear in pharmacies and hospitals out of nowhere, yet the logistics of transporting these goods are a seldom acknowledged component of the healthcare industry supply chain. Behind…
PwC France’s pharma and life sciences industry leader speaks out about the consultancy’s positioning as partner of choice for advisory services in the pharmaceutical industry with more than 75 percent…
Sebastien Aguettant, president of the French Association of Pharmaceutical Contract Manufacturers (SPIS) and president of leading French CMO Delpharm, discusses the evolutions and growing significance of contract manufacturing, how CMO…
Genfit’s Jean-François Mouney speaks about responding to high unmet medical needs in inflammatory and metabolic related diseases. With the increase in obesity related diseases, Mouney discusses their lead pipeline product:…
Thépenier CEO Tsuyoshi Hasuo has imparted a unique vision to internationalize the Normandy-based French company encompassing a company turnaround and a maximization of growth potential. Together with Deputy CEO, Bertrand…
Eric Ducournau, CEO of Pierre Fabre Dermo-Cosmétique (PFDC), discusses the company’s revolutionary lines of dermatologically tested skincare products and their niche adapted internationalization strategy that is focused on providing the…
Growing awareness of start-up activity within France, fuelled by Minister for the Economy, Industry and Digital Affairs Emmanuel Macron’s ‘La French Tech program,’ is finally helping to place French start-ups…
See our Cookie Privacy Policy Here
